Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
Chr t(14;16)
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
Chr t(14;16)
Multiple Myeloma
Chr t(14;16)
Multiple Myeloma
Sensitive: B - Late Trials
Sensitive
:
B
Sensitive: B - Late Trials
Sensitive
:
B
Chr t(14;16)
Multiple Myeloma
Chr t(14;16)
Multiple Myeloma
daratumumab
Sensitive: B - Late Trials
daratumumab
Sensitive
:
B
daratumumab
Sensitive: B - Late Trials
daratumumab
Sensitive
:
B
Chr t(14;16)
Multiple Myeloma
Chr t(14;16)
Multiple Myeloma
lenalidomide + isatuximab-irfc
Sensitive: B - Late Trials
lenalidomide + isatuximab-irfc
Sensitive
:
B
lenalidomide + isatuximab-irfc
Sensitive: B - Late Trials
lenalidomide + isatuximab-irfc
Sensitive
:
B
Chr t(14;16)
Multiple Myeloma
Chr t(14;16)
Multiple Myeloma
ixazomib
Sensitive: C2 – Inclusion Criteria
ixazomib
Sensitive
:
C2
ixazomib
Sensitive: C2 – Inclusion Criteria
ixazomib
Sensitive
:
C2
Chr t(14;16)
Multiple Myeloma
Chr t(14;16)
Multiple Myeloma
Sensitive: C3 – Early Trials
Sensitive
:
C3
Sensitive: C3 – Early Trials
Sensitive
:
C3
Chr t(14;16)
Multiple Myeloma
Chr t(14;16)
Multiple Myeloma
Proteasome inhibitor + Immunomodulator
Sensitive: C3 – Early Trials
Proteasome inhibitor + Immunomodulator
Sensitive
:
C3
Proteasome inhibitor + Immunomodulator
Sensitive: C3 – Early Trials
Proteasome inhibitor + Immunomodulator
Sensitive
:
C3
Chr t(14;16)
Multiple Myeloma
Chr t(14;16)
Multiple Myeloma
lenalidomide + ixazomib
Sensitive: C3 – Early Trials
lenalidomide + ixazomib
Sensitive
:
C3
lenalidomide + ixazomib
Sensitive: C3 – Early Trials
lenalidomide + ixazomib
Sensitive
:
C3
Chr t(14;16)
Multiple Myeloma
Chr t(14;16)
Multiple Myeloma
lenalidomide + elotuzumab
Sensitive: C3 – Early Trials
lenalidomide + elotuzumab
Sensitive
:
C3
lenalidomide + elotuzumab
Sensitive: C3 – Early Trials
lenalidomide + elotuzumab
Sensitive
:
C3
Chr t(14;16)
Multiple Myeloma
Chr t(14;16)
Multiple Myeloma
lenalidomide
Sensitive: C3 – Early Trials
lenalidomide
Sensitive
:
C3
lenalidomide
Sensitive: C3 – Early Trials
lenalidomide
Sensitive
:
C3
Chr t(14;16)
Leukemia
Chr t(14;16)
Leukemia
lenalidomide
Resistant: C3 – Early Trials
lenalidomide
Resistant
:
C3
lenalidomide
Resistant: C3 – Early Trials
lenalidomide
Resistant
:
C3
Chr t(14;16)
Multiple Myeloma
Chr t(14;16)
Multiple Myeloma
elranatamab-bcmm
Sensitive: C3 – Early Trials
elranatamab-bcmm
Sensitive
:
C3
elranatamab-bcmm
Sensitive: C3 – Early Trials
elranatamab-bcmm
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login